Yang Wang

Dr. Yang Wang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SLSichan Li
Sichan Li
QYQi Ye
Qi Ye
HXHua Xu
Hua Xu
LZLong Zhang
Long Zhang
YWYang Wang
Yang Wang
Linezolid is a synthetic antibiotic very effective in the treatment of infections caused by Gram-positive pathogens. Although the clinical application of linezolid in children has increased progressively, data on linezolid pharmacokinetics in pediatric patients are very limited.

1 July 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
HPHui Peng
Hui Peng
PGPing Gao
Ping Gao
QXQiong Xu
Qiong Xu
MLMaochang Liu
Maochang Liu
JPJing Peng
Jing Peng
HXHua Xu
Hua Xu

5 May 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
LGLiuliu Gao
Liuliu Gao
HXHua Xu
Hua Xu
QYQi Ye
Qi Ye
SLSichan Li
Sichan Li
JWJun Wang
Jun Wang
YWYang Wang
Yang Wang
Objective: The purposes of our study were to investigate the population pharmacokinetics of teicoplanin in Chinese children with different renal functions and to propose the appropriate dosing regimen for these pediatric patients. Methods: We performed a prospective pharmacokinetic research on children aged 0–10 years, with different renal functions. The population pharmacokinetics model of teicoplanin was developed using NLME program. The individualized optimal dosage regimen was proposed on the basis of the obtained population pharmacokinetics parameters. Results: To achieve the target trough level of 10–30 mg/L, optimal dosing regimen for children with different renal functions are predicted as follows based on the population PK simulations: children with moderate renal insufficiency need three loading doses of 6 mg/kg q12h followed by a maintenance dose of 5 mg/kg qd; children with mild renal insufficiency require three loading doses of 12 mg/kg q12h followed by a maintenance dose of 8 mg/kg qd; children with normal or augmented renal function should be given three loading doses of 12 mg/kg q12h followed by a maintenance doses of 10 mg/kg qd. Conclusion: The first study on the population pharmacokinetics of teicoplanin in Chinese children with different renal functions was performed. Individualized dosing regimen was recommended for different renal function groups based on population PK model prediction.

17 August 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JWJun Wang
Jun Wang
HXHua Xu
Hua Xu
RLRan Li
Ran Li
SWSanlan Wu
Sanlan Wu
JZJili Zou
Jili Zou
YWYang Wang
Yang Wang
Objective: This study aimed to employ a population pharmacokinetic (PK) model to optimize the dosing regimen of voriconazole (VRC) in children with a critical illness. Methods: A total of 99 children aged from 0.44 to 13.58 years old were included in this study. The stability and predictive performance of the final model were evaluated by statistical and graphical methods. The optimal dosing regimen was proposed for children with different body weight, CYP2C19 phenotype, and co-administration with omeprazole. Results: The PK of VRC was described by a two-compartment model with nonlinear Michaelis-Menten elimination. Body weight, CYP2C19 phenotype, and omeprazole were significant covariates on maximum velocity of elimination (Vmax), which had an estimated typical value of 18.13 mg·h−1. Bayesian estimation suggested that dose-normalized concentration and total exposure (Cmax/D, Cmin/D, AUC24/D) were significantly different between extensive metabolizers (EM) patients and poor metabolizer (PM) patients. To achieve the target concentration early, two loading doses of 9 mg·kg−1 q12h were reliable for most children, whereas three loading doses of 6-7.5 mg·kg−1 q8h were warranted for young children weighted ≤18kg (except PM patients). The maintenance doses decreased about 30-40% in PM patients than that in EM patients. For children aged < 2 years in EM, the maintenance dose could be as high as 9 mg·kg−1. The maintenance dose of VRC was supposed to decrease slightly when co-administration with omeprazole. Conclusion: A population PK model of intravenous VRC for critically ill children has been successful developed. It is necessary to adjust dosing regimens according to CYP2C19 genotype. The optimal dosing regimens have been recommended basing on the final model.

2 March 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CNChang-He Niu
Chang-He Niu
HXHua Xu
Hua Xu
LGLiu-Liu Gao
Liu-Liu Gao
YNYing-Ming Nie
Ying-Ming Nie
LXLi-Peng Xing
Li-Peng Xing
YWYang Wang
Yang Wang
Caspofungin is the first echinocandin antifungal agent that licented for pediatric use in invasive candidiasis and aspergillosis. In this study, we evaluated the population pharmacokinetics of caspofungin and investigate appropriate dosing optimization against Candida spp. in children with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in order to improve therapeutic efficacy. All participants received a recommended caspofungin 70 mg/m2 loading dose followed by 50 mg/m2 maintenance dose. A one-compartment model with first-order elimination was best fitted the data from 48 pediatric patients. Body surface area and aspartate aminotransferase had significant influence on caspofungin clearance from covariate analysis. Our results reviewed that dose adjustment is not necessary in patients with mild liver dysfunction. Monte Carlo simulations were performed using pharmacokinetic data from our study to evaluate the probability of target attainment (PTA) of caspofungin regimen in terms of AUC24/MIC targets against Candida spp. The results of simulations predicted that a caspofungin 70 mg/m2 at first dose, 50 mg/m2 of daily dose may have a high probability of successful outcome against C. albicans and C. glabrata whilst 60 mg/m2 maintenance dose was required for fungistatic target against C. parapsilosis but may be not sufficient to achieve optimal fungicidal activity. Caspofungin standard regimen had high probability of successful outcome against C. albicans (MIC ⩽ 0.25 mg/L) and C. glabrata (MIC ⩽ 0.5 mg/L) but insufficient for C. parapsilosis with MIC > 0.25 mg/L. That may provide an evidence based support to caspofungin individualized administration and decrease the risk of therapeutic failure in allo-HSCT pediatric patients.

22 December 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SLSichan Li
Sichan Li
YWYueFei Wang
YueFei Wang
HDHui Dong
Hui Dong
YZYuan Zhu
Yuan Zhu
PCPeng Cao
Peng Cao
YWYang Wang
Yang Wang